Recursion Pharmaceuticals, Inc. RXRX Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$644.76M-39.1% | -$463.66M-41.3% | -$328.07M-37.0% | -$239.48M-28.4% | ||
| $83.7M+129% | $36.49M+49.6% | $24.4M+108% | $11.76M+39.9% | ||
| $111.22M+36.2% | $81.69M+52.7% | $53.5M+91.7% | $27.91M+88.0% | ||
| -$371.81M-3.5% | -$359.17M-24.8% | -$287.78M-245% | -$83.52M+47.3% | ||
| $6.47M-52.8% | $13.7M+14.6% | $11.96M-67.7% | $37.06M-6.9% | ||
| -$16.87M-106% | $260.06M+2,643% | -$10.23M-105% | $201.23M+174% | ||
| $8.43M+89.8% | $4.44M+480% | $766K+751% | $90K-99.3% | ||
| $521.53M+71.5% | $304.12M+117% | $140.13M-9.2% | $154.35M-67.1% | ||
| $150.9M— | —— | -$161.91M— | —— | ||
| -$378.28M-1.5% | -$372.87M-24.4% | -$299.74M-149% | -$120.58M+39.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Recursion Pharmaceuticals, Inc.'s cash flow data come from?
- Every line is extracted from Recursion Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.